Spin off companies

Although this is by no means expected from ICREA researchers, it so happens that sometimes they hit on something that shows promise of becoming a powerful new technology, but it seems impossible to develop that further without significant investment of time and money. In these cases, many choose to explore the option of creating a spin-off company dedicated to the concept.

List of spin off companies

  • MOSAIC BIOMEDICALS (Inactive)

    Jointly supported by the Vall d’Hebron Institut d’Oncologia (VHIO), the Vall d’Hebron Institut de Recerca (VHIR) and ICREA.
    Entrepreneur: ICREA Research Professor Joan Seoane.
    Born in April 2013. Liquidated in 2020.

  • logo nanobots therapeutics
    Nanobots Therapeutics SL

    Supported by IBEC and ICREA
    Entrepreneur: ICREA Research Professor Samuel Sánchez Ordoñez
    Born in Gener 2023

    view details
    CLOSE

    Nanobots Therapeutics SL

    Nanobots Therapeutics is a biomedical company developing a new modality of medicines for different types of cancers, based on our unique platform technology (MotionTx).

    Our mission is to develop more effective therapies for patients by increasing drug penetration into cancer cells.

    We’re utilizing our proprietary MotionTx technology platform to design, engineer, and develop therapeutics that combine the high and selective tumor penetration with the precision of targeted therapies in order to reach and kill cancer cells.

  • NOSTRUM BIODISCOVERY

    Supported by the Barcelona Supercomputing Center - Centro Nacional de Supercomputación (BSC-CNS), the Universitat de Barcelona (UB), the Institut de Recerca Bioèdica de Barcelona (IRB Barcelona) and ICREA.
    Entrepreneur: ICREA Research Professor Victor Guallar.
    Born in December 2015.

    view details
    CLOSE

    NOSTRUM BIODISCOVERY

    Nostrum Biodiscovery is a biotechnological company focused on the computational biology sector and specifically; in the structure-based drug design area dedicated to early drug discovery and development based on rational design techniques.

    For 12 years, Dr. Modesto Orozco and Dr. Victor Guallar supported by top-tier public research institutions as Barcelona SuperComputing Center (BSC), Institute for Research in Biomedine (IRB Barcelona), ICREA and Universitat de Barcelona (UB) have been developing innovative in silico tools to reduce pharmaceutical and biotechnological R&D costs while improving the productivity and future profitability of the drug discovery process.

    Nostrum Biodiscovery technologies represents a unique breakthrough in this field since they will be bringing key features to pharmaceutical discovery users as the new approach to molecular simulation, target characterization, drug recognition and an integrated molecular dynamics into the drug value chain. 

  • Nuage Therapeutics
    Nuage Therapeutics

    Supported by the Institut de Recerca Biomèdica (IRB Barcelona) and ICREA.
    Entrepreneur: ICREA Research Professor Xavier Salvatella.
    Born in July 2021.

    view details
    CLOSE

    Nuage Therapeutics

    Nuage Therapeutics (Nuage Tx) is a spin-off company from the Institute for Research in Biomedicine (IRB Barcelona) and ICREA, that stemmed from the Laboratory of Molecular Biophysics lead by Dr. Xavier Salvatella. The company was incorporated on 29th July 2021.

    The mission of Nuage Tx is to leverage biomolecular condensation and chemical biology to develop selective modulators of disordered proteins involved in challenging indications representing unmet medical needs.

    Nuage Tx was founded by Xavier Salvatella, Mateusz Biesaga and Denes Hnisz, a team of scientists with complementary expertise that provide unique perspective on targeting intrinsically disordered proteins. Xavier Salvatella is an ICREA Professor and Leader of the Laboratory of Molecular Biophysics at IRB Barcelona. He is a renowned expert in intrinsically disordered proteins, biomolecular condensation and the structural properties of the transactivation domain of androgen receptor. Mateusz Biesaga is a PhD student and an MSCA fellow at the laboratory of Xavier Salvatella. He holds a degree in biomedical engineering and has expertise in assay development and validation for drug discovery. Denes Hnisz is the Leader of Precision Gene Control group at the Max Planck Institute for Molecular Genetics in Berlin (Germany). He is a prominent expert in transcriptional control, nuclear condensates and genome structure.

    The first program of Nuage Tx aims to develop a potent and selective drug targeting the transactivation domain of androgen receptor to deliver a life-changing treatment to patients with castration-resistant prostate cancer. Nuage Tx is developing a proprietary Condensation Screening Assay and a Target Discovery Algorithm that will be used to identify new targets and new drug candidates. Nuage Tx aims to become a platform company with multiple assets in its pipeline.

    Nuage Tx has already in-licensed a patent application from the Institute for Research in Biomedicine (IRB Barcelona) related to a proprietary in vitro condensation assay developed at Dr. Xavier Salvatella’s lab. The core intellectual property of Nuage Tx will be based on protecting the drug candidates once they reach a sufficiently advanced development stage. Other patent applications from public institutions or private entities will be in-licensed, if deemed necessary, to strengthen Nuage Tx’s patent portfolio.

  • OMNIA MOLECULAR (Inactive)

    Jointly supported by the Parc Científic de Barcelona (PCB), the Institut de Recerca Biomèdica (IRB Barcelona) and ICREA.
    Entrepreneur: ICREA Research Professor Lluís Ribas de Pouplana.
    Born in June 2005.